Vertex Pharmaceuticals is working toward making its recently approved non-opioid pain medicine Journavx not only broadly ...

Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.

After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

Lately, one of America's leading pharmaceutical companies can't catch a break from Wall Street. Shares of Vertex ...

Operator Good day, and welcome to the Vertex Pharmaceuticals fourth quarter 2024 earnings call. All participants will be in a ...

Conestoga Capital Advisors, an asset management company, released its fourth-quarter 2024 investor letter. A copy of the ...

The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment ...

SpotDraft, an AI-driven contract lifecycle management platform, secures USD 54 million in Series B funding led by Vertex Growth Singapore and Trident Partners. The funding will accelerate global ...

SpotDraft’s software includes AI-assisted redlining tools, which is the process of editing a contract where two or more ...

AI-driven enterprise tech startup SpotDraft has raised $54 Mn in its Series B funding round led by Vertex Growth and Trident ...

Unfortunately, the stock market barely noticed Vertex's achievement ... Its lack of addictive properties is a huge selling point for physicians who don't want to start patients with acute pain ...